Valion Bio, Inc. Share-based Payment Arrangement, Expense
Valion Bio, Inc. (VBIO) reported Share-based Payment Arrangement, Expense of $133.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- Valion Bio, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $133.00K, a 24.86% decline year-over-year.
- Valion Bio, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $208.00K, a 108.00% increase year-over-year.
- Valion Bio, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $149.00K, a 136.51% increase year-over-year.
- Valion Bio, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $138.00K, a 137.93% increase year-over-year.
- Valion Bio, Inc. share-based payment arrangement, expense for fiscal 2025 was $564.00K, a 146.29% increase from fiscal 2024.
- Valion Bio, Inc. share-based payment arrangement, expense for fiscal 2024 was $229.00K, a 15.50% decline from fiscal 2023.
- Valion Bio, Inc. share-based payment arrangement, expense for fiscal 2023 was $271.00K, a 31.91% decline from fiscal 2022.
- Valion Bio, Inc. share-based payment arrangement, expense for fiscal 2022 was $398.00K, a 598.25% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $133.00K 10-Q · filed 2026-08-14 | $341.00K 10-Q · filed 2026-08-14 | $490.00K derived: sum of 3 quarters · filed 2026-08-14 | $628.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $208.00K 10-Q · filed 2026-05-14 | $357.00K derived: sum of 2 quarters · filed 2026-05-14 | $495.00K derived: sum of 3 quarters · filed 2026-05-14 | $672.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $287.00K derived: sum of 2 quarters · filed 2026-03-30 | $464.00K derived: sum of 3 quarters · filed 2026-08-14 | $564.00K 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $138.00K 10-Q · filed 2025-11-14 | $315.00K derived: sum of 2 quarters · filed 2026-08-14 | $415.00K 10-Q · filed 2025-11-14 | $478.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-06-30 | $177.00K 10-Q · filed 2026-08-14 | $277.00K 10-Q · filed 2026-08-14 | $340.00K derived: sum of 3 quarters · filed 2026-08-14 | $398.00K derived: sum of 4 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-14 | $163.00K derived: sum of 2 quarters · filed 2026-05-14 | $221.00K derived: sum of 3 quarters · filed 2026-05-14 | $275.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $121.00K derived: sum of 2 quarters · filed 2026-03-30 | $175.00K derived: sum of 3 quarters · filed 2026-03-30 | $229.00K 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $58.00K 10-Q · filed 2025-11-14 | $112.00K derived: sum of 2 quarters · filed 2025-11-14 | $166.00K 10-Q · filed 2025-11-14 | $224.00K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $54.00K 10-Q · filed 2025-08-14 | $108.00K 10-Q · filed 2025-08-14 | $166.00K derived: sum of 3 quarters · filed 2025-08-14 | $214.00K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $54.00K 10-Q · filed 2025-05-15 | $112.00K derived: sum of 2 quarters · filed 2025-05-15 | $160.00K derived: sum of 3 quarters · filed 2025-05-15 | $241.00K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $106.00K derived: sum of 2 quarters · filed 2025-03-21 | $187.00K derived: sum of 3 quarters · filed 2025-03-21 | $271.00K 10-K · filed 2025-03-21 | ||
| 2023-09-30 | $48.00K 10-Q · filed 2024-11-14 | $129.00K derived: sum of 2 quarters · filed 2024-11-14 | $213.00K 10-Q · filed 2024-11-14 | $438.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $81.00K 10-Q · filed 2024-08-14 | $165.00K 10-Q · filed 2024-08-14 | $390.00K derived: sum of 3 quarters · filed 2024-08-14 | $502.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $84.00K 10-Q · filed 2024-05-15 | $309.00K derived: sum of 2 quarters · filed 2024-05-15 | $421.00K derived: sum of 3 quarters · filed 2024-05-15 | $533.00K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $337.00K derived: sum of 2 quarters · filed 2024-03-25 | $449.00K derived: sum of 3 quarters · filed 2024-03-25 | $398.00K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $112.00K 10-Q · filed 2023-11-14 | $113.00K 10-Q · filed 2022-11-14 | $224.00K derived: sum of 2 quarters · filed 2023-11-14 | $173.00K 10-Q · filed 2023-11-14 | $286.00K 10-Q · filed 2022-11-14 | $301.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $112.00K 10-Q · filed 2023-08-14 | $173.00K 10-Q · filed 2023-08-14 | $189.00K derived: sum of 3 quarters · filed 2023-08-14 | $212.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $61.00K 10-Q · filed 2023-05-15 | $77.00K derived: sum of 2 quarters · filed 2023-05-15 | $100.00K derived: sum of 3 quarters · filed 2023-05-15 | $108.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $39.00K derived: sum of 2 quarters · filed 2023-03-31 | $47.00K derived: sum of 3 quarters · filed 2023-03-31 | $57.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $23.00K 10-Q · filed 2022-11-14 | $31.00K derived: sum of 2 quarters · filed 2022-11-14 | $41.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $8.00K 10-Q · filed 2022-08-15 | $18.00K 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |